GSK-649868
GSK-649868 is an experimental drug that was developed by GlaxoSmithKline for the treatment of insomnia. It acts as a selective antagonist for the orexin receptor, specifically the OX2 subtype, and has sedative effects.
Pharmacology[edit | edit source]
GSK-649868 is a selective antagonist for the orexin receptor, specifically the OX2 subtype. Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. By blocking the action of orexin, GSK-649868 promotes sleep.
Clinical trials[edit | edit source]
GSK-649868 has undergone Phase II clinical trials for the treatment of insomnia. However, as of 2021, it has not been approved for use by any regulatory authority.
See also[edit | edit source]
References[edit | edit source]
| GSK-649868 Resources | ||
|---|---|---|
|
| |
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
